European Union · Phase III · Early-stage focus
Which EU sites and PIs have Phase III Parkinson’s trial experience?
Krakowska Akademia Neurologii, La Princesa University Hospital and Neuro-Care each appear in four Phase III Parkinson’s trials. For early-stage disease, PARAISO spans 84 EU sites in nine countries and plans 900 participants globally.
across all disease stages
across six randomized trials
Top 10 sites · Parkinson’s across all stages
Three sites share the lead with four trials each
The leading sites are in Kraków, Madrid and Katowice. Nine of the ten sites below also participate in the early-stage PARAISO trial.
Results for early-stage Parkinson’s:
PARAISOPhase III · One early-stage trial84 sites across nine EU countries. Each site has one dedicated early-stage Phase III trial, so the broader experience above helps distinguish them.
BHV-8000Phase II/III · Shown separately101 sites across ten EU countries. 39 sites also appear in PARAISO.
Top 10 principal investigators · All stages
Four PIs each appear in four Phase III trials
Fabrizio Stocchi, Gabriela Kłodowska, Lydia López Manzanares and Monika Rudzińska-Bar share the lead. Nine of the ten investigators below also appear in PARAISO.
Top 10 countries · Parkinson’s across all stages
Italy has the broadest Phase III trial footprint
Italy appears in five trials, followed by Poland and Spain with four each. France and Germany each appear in three.
Results for early-stage Parkinson’s:
PARAISOPhase III · Early-stageNine EU countries, each with one trial. Italy, Poland and Spain combine early-stage participation with the broadest Phase III activity.
BHV-8000Phase II/III · Early-stageTen EU countries. Belgium and Czechia extend beyond PARAISO’s footprint, while Denmark appears only in PARAISO.
A multinational trial can appear in more than one country. Countries are EU member states.
Average sample size · Parkinson’s across all stages
Planned sample size averages 255 participants
The six randomized Phase III trials have a median target of 121 participants and a range of 60 to 900. PARAISO is the largest and the dedicated early-stage Phase III comparator.
Results for early-stage Parkinson’s:
PARAISOPhase III · Early-stage900 planned participants. One dedicated trial provides a size reference, rather than a multi-trial average.
BHV-8000Phase II/III · Early-stage550 planned participants, analyzed separately from Phase III.
Targets cover the whole trial, including countries outside the EU. TEMPO-4 plans up to 1,200 participants in an open-label extension and contributes to experience rankings, but not the randomized sample-size average.
Coverage: Trial Agents’ CTIS collection as of 15 September 2026. Source: CTIS trial records and protocols, as of 15 September 2026, with PARAISO and BHV-8000 registry records. The broad group spans early-stage disease, mixed-stage extension populations and Parkinson’s with motor fluctuations or freezing of gait.
Rankings count distinct trial listings, including planned and historical involvement. They indicate experience, not recruitment capacity or performance. Separate hospital locations remain separate sites. Ties are ordered alphabetically, including ties at the tenth position.